Cambridge biotech Apnimed raised $192 million in its IPO and will begin trading on Nasdaq as the company awaits an FDA decision on its sleep apnea treatment.

Writing, it turns out, can be a funny thing. It seems I spend a lot of time thinking that I have been misunderstood about something. Long ago it dawned on ...